Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
Systemic sclerosis (SSc) is a multisystem autoimmune disease chracterized by vasculopathy and fibrosis of the skin and various internal organs. We recently established a new experimental system in which the three pathological features of SSc, such as immune abnormality, vasculopathy, and tissue fibrosis, can be separately assessed by using endothelial cell-specific Fli1 knockout mice, which mimic SSc vasculopathy, and bleomycin-treated mice, which resemble inflammation and tissue fibrosis of SSc.In this study, we identified the mechanisms by which glycyrrhizin and cyclophosphamide affect the developmental process of SSc by using this experimental system. At the time of writing, glycyrrhizin is applied for a patent, and we are conducting a prospective clinical study to evaluate the efficacy of glycyrrhizin on SSc vasculopathy.
|